In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $8.00. The company’s shares opened today at $3.45.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Gritstone Oncology, and Opko Health. According to TipRanks, Tenthoff has an average return of 3.5% and a 33.86% success rate on recommended stocks.
Tempest Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $27.50, representing a 697.10% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Tempest Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.58 million. In comparison, last year the company had a GAAP net loss of $9.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tempest Therapeutics (TPST) Company Description:
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
Read More on TPST:
- Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
- Four new option listings and nineteen option delistings on October 24th
- Tempest Therpeutics trading resumes
- Tempest Therpeutics trading halted, volatility trading pause
- Tempest Therapeutics (NASDAQ:TPST) Explodes 2,100% Higher on New Data Release
